Clinical Trial Update: Treatment of Patients With Donor Lymphocytes Sensitized by Antigens Expressed by the Host [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating donor lymphocytes sensitized by host antigens was withdrawn. The sponsor was Hadassah Medical Organization.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Hematologic Malignancies

Drugs mentioned

• Donor lymphocytes sensitized by host antigens

Snippet

Sponsor: Hadassah Medical Organization | Conditions: Hematological Malignancy, Neoplasm Metastasis | Phase 2 | Status: WITHDRAWN